Monopar Therapeutics (NASDAQ:MNPR) Hits New 1-Year High - Time to Buy?

Key Points

• Monopar Therapeutics stock reached a new 52-week high of $104.75, closing at $103.97 with a trading volume of 4,842 shares.
• Analysts have a **consensus rating** of "Moderate Buy" for the stock, with price targets set as high as **$142.00** by Raymond James Financial.
• Insider trading activity included CEO Chandler Robinson selling 16,800 shares, resulting in an **18.61% decrease** in his ownership position.

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) reached a new 52-week high on Monday . The company traded as high as $104.75 and last traded at $103.97, with a volume of 4842 shares changing hands. The stock had previously closed at $99.39.

Wall Street Analyst Weigh In

A number of brokerages have commented on MNPR. BTIG Research upped their price target on Monopar Therapeutics from $87.00 to $104.00 and gave the stock a "buy" rating in a research report on Thursday, September 25th. Chardan Capital upped their price target on Monopar Therapeutics from $60.00 to $85.00 and gave the stock a "buy" rating in a research report on Thursday, September 25th. Oppenheimer set a $115.00 price target on Monopar Therapeutics and gave the stock an "outperform" rating in a research report on Thursday. Cantor Fitzgerald restated an "overweight" rating on shares of Monopar Therapeutics in a research report on Wednesday, September 24th. Finally, Raymond James Financial set a $142.00 price target on Monopar Therapeutics and gave the stock a "strong-buy" rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $97.33.

Monopar Therapeutics Trading Up 2.5%

The stock has a 50-day simple moving average of $48.63 and a two-hundred day simple moving average of $41.29. The firm has a market capitalization of $628.51 million, a P/E ratio of -30.48 and a beta of 1.42.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.12. As a group, research analysts expect that Monopar Therapeutics Inc. will post -1.65 EPS for the current year.

Insider Buying and Selling

In other news, CEO Chandler Robinson sold 16,800 shares of the business's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the transaction, the chief executive officer directly owned 73,472 shares of the company's stock, valued at approximately $2,938,880. The trade was a 18.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Tactic Pharma Llc sold 550,229 shares of the business's stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $63.61, for a total value of $35,000,066.69. Following the transaction, the insider owned 272,026 shares in the company, valued at approximately $17,303,573.86. This trade represents a 66.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 592,733 shares of company stock valued at $36,700,227. 20.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Monopar Therapeutics in the second quarter valued at about $34,000. AlphaQuest LLC purchased a new position in Monopar Therapeutics during the first quarter worth approximately $44,000. JPMorgan Chase & Co. boosted its position in Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after purchasing an additional 1,821 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Monopar Therapeutics during the second quarter worth approximately $80,000. Finally, New York State Common Retirement Fund purchased a new position in Monopar Therapeutics during the second quarter worth approximately $104,000. 1.83% of the stock is owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.